Open an account

Seres Therapeutics

MCRB · NASDAQ

$2.31−$0.11 (−4.55%)TodayMarket closed ·
Prev close $2.42

MCRB analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $17.34 (+650.6% upside)

Low
$12.12
Now
$2.31
High
$23.10

Upgrades and downgrades

The latest rating actions, newest first

MCRB analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Jun 23, 2026InitiatesBuy
Canaccord GenuityMar 13, 2026MaintainsBuy

The case for and against

Updated Sep 3, 2026

Bull case

Seres Therapeutics is utilizing cutting-edge technology and acquiring partnerships to develop live biotherapeutic products for bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. Their drug SER-155 has shown early success in reducing infections and has secured partnerships and funding for future development, including the acquisition of VOWST by Nestlé. While there are market risks and competition in the industry, Seres Therapeutics has a strong pipeline and potential for growth in the growing field of microbiome-based treatments. Additionally, the promising results from their Phase 1b trial and the potential for additional treatments through their MbTx platform make this company a strong investment opportunity.

Bear case

Seres Therapeutics is a clinical stage biotechnology company with a single reportable segment focused on developing microbiome-based therapies for bacterial infections and gastrointestinal immune diseases. Despite its promising pipeline, the company has yet to generate significant revenue and is likely to require additional fundraising efforts, which could lead to dilution for current investors. Additionally, the company faces potential commercial risks, such as convincing medical professionals and insurers to adopt its novel treatments. Furthermore, there is a potential downside to the company's stock if the FDA requires additional data on safety or delays approval for its lead asset SER-109. Overall, due to these factors, the analyst has a negative outlook on Seres Therapeutics' stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.